Immatics NV
NASDAQ:IMTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.58
13.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Immatics NV
Immatics NV
Other Liabilities
Immatics NV
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immatics NV
NASDAQ:IMTX
|
Other Liabilities
€115.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Other Liabilities
€459.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Other Liabilities
€1.3B
|
CAGR 3-Years
35%
|
CAGR 5-Years
417%
|
CAGR 10-Years
37%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Other Liabilities
€48.1m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Other Liabilities
€109m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Formycon AG
XETRA:FYB
|
Other Liabilities
€187.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
273%
|
CAGR 10-Years
N/A
|
|
Immatics NV
Glance View
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
See Also
What is Immatics NV's Other Liabilities?
Other Liabilities
115.5m
EUR
Based on the financial report for Dec 31, 2023, Immatics NV's Other Liabilities amounts to 115.5m EUR.
What is Immatics NV's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
95%
Over the last year, the Other Liabilities growth was 52%. The average annual Other Liabilities growth rates for Immatics NV have been 11% over the past three years , 95% over the past five years .
You don't have any saved screeners yet
